We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

4 hedge funds and large institutions have $239K invested in Windtree Therapeutics in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more capital invested

Capital invested by funds: $194K → $239K (+$44.7K)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

33% less funds holding

Funds holding: 6 → 4 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$258K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$98.2K
2
VF
Virtu Financial
New York
-$28K
3
Citadel Advisors
Citadel Advisors
Florida
-$11.5K
4
UBS Group
UBS Group
Switzerland
-$382
5
Morgan Stanley
Morgan Stanley
New York
-$1

WINT Hedge Fund Activity: Q1 2024 in Review

4 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q1 2024, worth a combined $239K — up 23% from $194K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of WINT and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Deerfield Management, opening a new position worth an estimated $258K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $98.2K sold.

  • 4 institutional investors held Windtree Therapeutics (WINT) as of Q1 2024, down from 6 in Q4 2023.
  • Funds reported $239K of Windtree Therapeutics stock for Q1 2024, up 23% quarter-over-quarter.
  • 1 fund opened new Windtree Therapeutics positions in Q1 2024 and 3 closed out, a net change of -2 holders.
  • The largest Windtree Therapeutics buyer in Q1 2024 was Deerfield Management, an estimated $258K added.
  • The largest Windtree Therapeutics seller in Q1 2024 was Alyeska Investment Group, an estimated $98.2K sold.

Based on aggregated 13F filings for Q1 2024.